Is Dihexa Safe or Legal? What We Know

Key takeaways

• Nobody can say dihexa is safe, because it has never been tested in a person. FDA says it has not identified any human exposure data by any route, and we found no published animal toxicology study.
• It is not legal to obtain as a medicine. No US pharmacy may compound it; it came off FDA's Category 2 list on April 15, 2026 only because its nomination was withdrawn, and an advisory committee review is due by February 2027. Possession is not a crime; selling it for human use is.
• The cancer concern is about the pathway, not about evidence of harm. HGF/MET signaling drives growth and spread in several cancers, and dihexa is said to amplify it. Nobody has tested dihexa in a tumor model, and there is no evidence it causes cancer.
• The only human safety data in the family belong to fosgonimeton, a different injectable drug that its developer says becomes dihexa in the blood. In its 26-week trial, serious events were no more common than on placebo, but three times as many people stopped because of side effects.
• Anyone with cancer or a high cancer risk, anyone pregnant or breastfeeding, and anyone seeking treatment for memory loss or ADHD should not use it; those conditions have tested options.

The direct answer: nobody knows whether dihexa is safe, because it has never been given to people in a registered trial and FDA has found no human exposure data for it by any route (FDA Category 2). It is also not legal to get as a medicine in the United States: no licensed pharmacy may compound it. What follows is everything that is known, set against what is not. Our dihexa profile covers what it is and the evidence for its effects, and our dihexa dosage page explains why there is no human dose.

The safety record, source by source

Two cautions on the fosgonimeton rows. First, it is a different drug: dihexa with a phosphate group attached, made to pharmaceutical standards and injected under the skin at fixed doses. Athira Pharma, which licensed dihexa, abandoned it in 2015 and describes fosgonimeton as a prodrug converted in the blood into dihexa (Athira 2021). Second, its active form lasted about 1.5 hours in human blood (Hua 2022), and those trials lasted 26 weeks at most. Neither fact tells you what a capsule of unknown content, taken for months, does. The fosgonimeton data describe a tested product; they do not make research dihexa safe.

The cancer question: what is established and what is extrapolation

This is the concern raised most often, and it deserves precision.

Established. Hepatocyte growth factor (HGF) and its receptor, the tyrosine kinase MET, have a causal role in the hallmarks of cancer: cell survival, growth, new blood-vessel formation and metastasis (Gherardi 2012). MET is a validated cancer target in people: FDA approved capmatinib on May 6, 2020 and tepotinib on February 3, 2021 for metastatic non-small-cell lung cancer driven by MET exon 14 skipping mutations, with response rates of 41% to 68% in the pivotal trials (Mathieu 2022).

The premise. Dihexa's developers proposed that it binds HGF and helps it activate MET, so that small amounts of HGF signal more strongly. The paper that made that case was retracted in April 2025, though an independent 2025 rat study found that MET blockers cancelled dihexa's effect on memory, as our dihexa profile explains. So even the mechanism behind the concern is only partly established.

Extrapolation. If dihexa does amplify HGF/MET signaling, and if it reaches tumor tissue at active levels, it could in theory help an existing cancer grow or spread, particularly one that depends on MET. Neither "if" has been tested. We found no study of dihexa in any tumor model, cell line or animal, and nothing that measured dihexa levels outside the brain and blood.

Not established. That dihexa causes cancer. There is no evidence for that, and no one should claim it. The accurate statement is narrower: dihexa is designed to push on a pathway that cancers exploit, it may persist for days (in rats, at least), and nobody has checked what that means for a person with a tumor, known or undiagnosed.

Other risks worth naming

• An unknown product. Research dihexa is synthesized by chemical suppliers, sold without a pharmacy label, and not tested by anyone accountable for identity, purity, dose or sterility. Injectable vials add the risks of contamination and endotoxin.
• An unstudied brain drug. Dihexa was designed to cross into the brain and change how synapses form. Its effects on mood, sleep, seizure threshold, blood pressure or other medicines have never been studied in people.
• Persistence. If anything like the rat half-life held in people, a side effect would not stop when the capsules did. The human figure is unknown.
• A damaged evidence base. The founding paper carries an expression of concern and the mechanism paper was retracted. Safety judgments built on those papers inherit their uncertainty.

Who should not take dihexa

• Anyone with cancer, a history of cancer or a high inherited cancer risk, for the reasons above.
• Anyone pregnant, trying to conceive or breastfeeding. There are no reproductive data of any kind.
• Children and teenagers, whose brains are still developing.
• Anyone seeking treatment for memory loss, dementia or ADHD. These conditions have treatments that were tested in large trials. For ADHD, a network meta-analysis of 133 double-blind randomized trials supported methylphenidate in children and adolescents and amphetamines in adults as first-choice short-term medications (Cortese 2018). For early Alzheimer's disease, lecanemab slowed decline by 0.45 points on an 18-point dementia scale over 18 months, with infusion reactions and brain-swelling findings on MRI that require monitoring (van Dyck 2023). Whether either is right for you is a clinician's call, and it starts with an evaluation. Our cognitive-function ranking explains what that evaluation looks for.

Is dihexa legal?

Consistent with our legal tracker, as of October 2026:

• Not approved. Dihexa is not FDA-approved for any use and has never been tested in a registered human trial.
• Not compoundable. A 503A pharmacy may compound a substance only if it has a USP monograph, is a component of an FDA-approved drug or is on FDA's bulks list. Dihexa passes none of the three tests, so a prescription cannot make it available from a licensed pharmacy.
• Off Category 2, not permitted. FDA announced on April 15, 2026 that twelve peptides, dihexa among them, were coming off Category 2 because their nominations had been withdrawn. FDA now lists dihexa acetate as "nominated but withdrawn" (FDA Category 2). Removal ended the safety flag; it did not make dihexa compoundable.
• Review pending. FDA's Pharmacy Compounding Advisory Committee is due to review dihexa, with LL-37, injectable GHK-Cu, PEG-MGF and melanotan II, by February 2027. A favorable vote would be advice only; FDA would then need to complete rulemaking.
• Possession versus sale. Peptides are not controlled substances, so having dihexa is not a crime. Selling it for human use is selling an unapproved drug, and a research-use-only label does not change that; FDA's 2026 warning letters cited dosing guides, calculators and bundled bacteriostatic water as evidence of intended human use.

That is also why we give no reconstitution example or units table for dihexa. Our reconstitution calculator is for medications a pharmacy has dispensed with a labeled concentration, and no dihexa product has one.

If you have already taken it

There is no monitoring protocol, because no clinician can legally prescribe dihexa. Tell your doctor what you took, how much, for how long and where it came from, and keep the container. Because its side effects are unknown, treat any new symptom after starting it as possibly related. Seek urgent care for signs of a severe allergic reaction (swelling of the face or throat, trouble breathing, widespread hives), a seizure, sudden severe headache, new confusion or weakness, or chest pain. Our guide to peptide side effects covers the problems that research injections cause in general.

Bottom line

Is dihexa safe? The honest answer is that it has not been tested, which is different from being safe. There is no human trial, no human exposure data at FDA, no published toxicology, a rat half-life measured in days, and a target pathway that cancers use. The only human data in the family belong to a different drug that was tested properly, did not help in Alzheimer's disease and caused enough injection-site trouble that three times as many people quit. Is it legal? You will not be prosecuted for owning it, but no pharmacy may make it and no one may lawfully sell it to you as a medicine. If memory or attention is the problem, the tested options start with a clinician.

Frequently asked questions

+−Is dihexa safe?

Nobody can say, because dihexa has never been tested in a person. There is no human trial, FDA says it found no human exposure data by any route, and we found no published animal toxicology study. The rodent studies measured memory, not harm. 'No reported side effects' for dihexa means no one has looked, not that it is harmless.

+−Is dihexa legal in the US?

Possessing it is not a crime, but there is no legal way to get it as a medicine. It is not FDA-approved and no licensed pharmacy may compound it, because it is not on FDA's list of permitted bulk substances. It came off FDA's Category 2 safety-risk list on April 15, 2026 only because its nomination was withdrawn, and an FDA advisory committee review is due by February 2027. Selling it for human use, including with a research-use-only label, is selling an unapproved drug.

+−Does dihexa cause cancer?

There is no evidence that it does, and no study has tested it. The concern is about the pathway: dihexa is said to amplify signaling by hepatocyte growth factor (HGF) through its receptor MET, and HGF/MET signaling is an established driver of growth and spread in several cancers, which is why FDA has approved two MET-blocking drugs for a form of lung cancer. Whether dihexa could feed an existing tumor is unknown.

+−What are the side effects of dihexa?

They are unknown. No human study has recorded them. Forum reports cannot separate dihexa's effects from those of whatever else is in an unverified research product. The closest human data come from fosgonimeton, a different injectable drug that its developer says becomes dihexa in the blood: in its main trial, 14.2% stopped because of side effects, mostly injection-site reactions, versus 4.6% on placebo.

+−Has dihexa been tested in humans?

No. ClinicalTrials.gov lists no study of dihexa under its name, its code name PNB-0408 or its chemical name (searched October 10, 2026), and we found no published human study. Fosgonimeton, a related but different drug, has been tested, and its 26-week Alzheimer's trial missed every primary and secondary goal.

+−Is it legal to buy dihexa online?

The products sold online are research chemicals, and selling them for human use is selling an unapproved drug whatever the label says; in 2026 FDA's warning letters to research-peptide sellers cited dosing guides and calculators as evidence of intended human use. Buyers are not prosecuted for possession, but they get a product nobody has tested for identity, purity or sterility, with no pharmacist or prescriber in the chain.

+−Can dihexa help with ADHD or memory loss?

There is no human evidence that it can; it has never been tested for either. Both conditions have treatments tested in large trials, from ADHD medications studied in more than 130 randomized trials to approved drugs for early Alzheimer's disease, and both deserve a clinician's evaluation rather than a research chemical.

Sources

1. RegulatoryFDA. Certain bulk drug substances for use in compounding that may present significant safety risks: Category 2 list and bulk drug substances nominated but withdrawn (dihexa acetate). Content current as of April 22, 2026. (2026)
2. SourceClinicalTrials.gov. Searches for 'dihexa', 'PNB-0408' and 'N-hexanoic-Tyr-Ile': no registered studies (searched October 10, 2026). (2026)
3. StudyMcCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther 2013;344:141-54. Expression of concern published 2021 (J Pharmacol Exp Ther 378:313). (2013)
4. ReviewGherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103. (2012)
5. ReviewMathieu LN et al. FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res 2022;28:249-54. (2022)
6. SourceAthira Pharma, Inc. Form 8-K filed October 21, 2021: dihexa development 2011 to 2015 and its discontinuation; ATH-1017 (fosgonimeton) described as a prodrug that metabolizes in plasma into dihexa. (2021)
7. StudyHua X et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer's disease: randomized, placebo-controlled, double-blind, phase I clinical trial. J Alzheimers Dis 2022;86:1399-413. (2022)
8. StudyPorsteinsson AP et al. Fosgonimeton in mild-to-moderate Alzheimer's disease (LIFT-AD). J Alzheimers Dis Rep 2025;9:25424823251405817. (2025)
9. Studyvan Dyck CH et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023;388:9-21. (2023)
10. ReviewCortese S et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-38. (2018)